secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-013816
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon FY2025 net loss $14.5M; Phase 2 OS benefit 14.7 months
-------------------------------------------------------------

- Net loss for 2025 was $14.5M ($6.83/sh) vs $18.6M ($16.94/sh) in 2024; operating expenses down 23%.
- Final Phase 2 OVATION 2 data show median OS improvement of 14.7 months (45.1 vs 30.4 months) with IMNN-001+SoC vs SoC alone.
- Phase 3 OVATION 3 enrollment ahead of plan; first patient dosed in Q3 2025.
- Cash and cash equivalents $8.8M as of Dec 31, 2025; $7M registered direct offering closed Dec 2025.
- Strategic reorganization Feb 2026 to reduce expenses and focus on Phase 3 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/0001493152-26-013816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer